Stratos Wealth Partners LTD. Cuts Stock Position in Sanofi (NASDAQ:SNY)

Stratos Wealth Partners LTD. cut its holdings in Sanofi (NASDAQ:SNY) by 21.9% in the fourth quarter, Holdings Channel reports. The institutional investor owned 4,991 shares of the company’s stock after selling 1,398 shares during the quarter. Stratos Wealth Partners LTD.’s holdings in Sanofi were worth $248,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Fairfield Bush & CO. purchased a new stake in shares of Sanofi during the first quarter worth approximately $26,000. Bank of New York Mellon Corp increased its position in shares of Sanofi by 31.3% during the first quarter. Bank of New York Mellon Corp now owns 440,646 shares of the company’s stock worth $22,623,000 after purchasing an additional 105,046 shares in the last quarter. Cambridge Investment Research Advisors Inc. increased its position in shares of Sanofi by 12.9% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 24,613 shares of the company’s stock worth $1,264,000 after purchasing an additional 2,805 shares in the last quarter. Yousif Capital Management LLC increased its position in shares of Sanofi by 45.2% during the first quarter. Yousif Capital Management LLC now owns 42,041 shares of the company’s stock worth $2,158,000 after purchasing an additional 13,095 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its position in shares of Sanofi by 0.5% during the first quarter. Dimensional Fund Advisors LP now owns 300,009 shares of the company’s stock worth $15,402,000 after purchasing an additional 1,391 shares in the last quarter. 10.04% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

SNY has been the subject of several research reports. StockNews.com cut Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 27th. Morgan Stanley assumed coverage on Sanofi in a research report on Tuesday, January 23rd. They set an “equal weight” rating and a $55.00 price target for the company. Finally, TheStreet lowered Sanofi from a “b” rating to a “c” rating in a research note on Friday, February 9th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $55.00.

Sanofi Stock Performance

NASDAQ SNY opened at $46.24 on Tuesday. The stock’s fifty day moving average is $47.59 and its two-hundred day moving average is $48.76. The firm has a market capitalization of $116.97 billion, a P/E ratio of 19.59, a price-to-earnings-growth ratio of 1.72 and a beta of 0.61. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.27. Sanofi has a fifty-two week low of $42.63 and a fifty-two week high of $57.82.

Sanofi (NASDAQ:SNY) last released its quarterly earnings data on Thursday, February 1st. The company reported $0.89 earnings per share for the quarter, missing analysts’ consensus estimates of $0.94 by ($0.05). The company had revenue of $11.76 billion for the quarter, compared to analyst estimates of $13.02 billion. Sanofi had a return on equity of 27.47% and a net margin of 12.56%. On average, research analysts anticipate that Sanofi will post 4.16 earnings per share for the current year.

Sanofi Increases Dividend

The firm also recently declared an annual dividend, which will be paid on Thursday, June 6th. Stockholders of record on Friday, May 10th will be paid a $1.478 dividend. This represents a dividend yield of 2.98%. The ex-dividend date of this dividend is Thursday, May 9th. This is a positive change from Sanofi’s previous annual dividend of $1.38. Sanofi’s dividend payout ratio is 58.47%.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.